Patheon IncTSX: PTI

Patheon Announces Changes to its Commercial Operations Structure

· Issued by Patheon Inc via CNW

TORONTO, May 21, 2013 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry, announced today that Antonella Mancuso, President, Global Commercial Operations and Chief Manufacturing Officer, notified the company that she plans to resign from her positions with the company and its subsidiaries, effective July 10, 2013.

About Patheon Inc.

Patheon Inc. (TSX: PTI) is a leading provider of contract development and commercial manufacturing services to the global pharmaceutical industry for a full array of solid and sterile dosage forms.  Through the company's recent acquisition of Banner Pharmacaps - a market leader in soft gelatin capsule technology - Patheon now also includes a proprietary products and technology business.

Patheon provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies.  The company's integrated network consists of 18 locations, including 14 commercial contract manufacturing facilities and 12 development centers across North America and Europe.  Patheon enables customer products to be launched with confidence anywhere in the world.  For more information visit www.patheon.com.

SOURCE Patheon Inc

SOURCE: Patheon Inc.

Contact: 
Jennifer Almond
Senior Representative, Corporate Communications & Investor Relations
919 226 3200
investorrelations@patheon.com

Copyright CNW Group 2013

View original source (CNW)Patheon Inc on 6ix

Story so far

Earlier from Patheon

Later from Patheon

All Patheon news releases